Benchmark’s Bill Gurley, CoreWeave Strikes Deal with Anthropic, New Treatment for Pancreatic Cancer 4/10/26

Concerns grow over AI’s cyber security risks with the Fed Chair and Treasury Secretary meeting with bank executives. Legendary investor Bill Gurley lays out his thoughts on the rapidly changing landscape. Then CoreWeave inking yet another deal with a major AI player, this time Anthropic. We look at the bull and bear cases for the stock. And a new treatment from Revolution Medicines targets one of the deadliest forms of cancer, pancreatic.   Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.